Abstract
Recently a new β 2 stimulant “Dopexamine” has been developed and is expected to be effective in the treatment of congestive heart failure (CHF). We used it in a case of severe CHF in ventricular septal rupture due to anterior myocardial infarction and saw excellent improvement. The usefulness of this drug in severely reduced cardiac function is discussed in this paper.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Refrences
Smith GW, Hall JC, Farmer JB (1987) The cardiovascular actions of dopexamine hydrochloride, an agonist at dopamine receptors and β 2- adrenoceptors in the dog. J Pharm Pharmacol 39:636–641.
Brown RA, Dixon J, Farmer JB (1985) Dopexamine: a novel agonist at peripheral dopamine receptors and β 2- adrenoceptors. Br J Pharmacol 85: 599–608.
Dawson JR, Thompson DS, Signy FS (1985) Acute heamodynamic and metabolic effects of dopexamine, a new dopaminergic receptor ago¬nist, in patients with chronic heart failure. Br Heart J 54: 313–320.
Hakim M, Foulds H, Latimer RD, English TAM (1988) Dopexamine hydrochroride, a β 2- adrenergic and dopaminergic agonist;heamodynamic effects following cardiac surgery. Eur Heart J 9:853–858.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1992 Springer-Verlag Tokyo
About this paper
Cite this paper
Ishikawa, Y., Kudoh, M., Ohmura, M., Sato, T., Miyashita, H. (1992). Remarkable Improvement in Congestive Heart Failure in Ventricular Septal Rupture by Dopexamine Infusion. In: Yasuda, H., Kawaguchi, H. (eds) New Aspects in the Treatment of Failing Heart. Springer, Tokyo. https://doi.org/10.1007/978-4-431-68219-6_37
Download citation
DOI: https://doi.org/10.1007/978-4-431-68219-6_37
Publisher Name: Springer, Tokyo
Print ISBN: 978-4-431-68221-9
Online ISBN: 978-4-431-68219-6
eBook Packages: Springer Book Archive